Arena Pharma (ARNA) BELVIQ Trends Remain Underwhelming, BMO Capital Notes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. SPY
9. FIX
10. IVBIY

Go back to Arena Pharma (ARNA) BELVIQ Trends Remain Underwhelming, BMO Capital Notes

Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2015 Financial Results

May 11, 2015 4:07 PM EDT

SAN DIEGO, May 11, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2015.

"We are pleased with the progress we have made thus far in 2015, including the approval and launch of BELVIQ in South Korea, our entry into a collaboration for the development and commercialization of nelotanserin, and the favorable results generated from our investigational clinical trials for APD334 for inflammatory bowel diseases, APD371 for pain or fibrotic diseases and BELVIQ XR, a once-daily extended release formulation of... More